Blinatumomab

贝林妥欧单抗

Report date: 2026/04/17 20:02:02
First In Class

Base Information

Drug NameBlinatumomab
Drug Alias NameBlinatumomabum兰妥莫单抗倍林妥莫双抗布利妥莫单抗博纳吐单抗 +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > T cell engagers
Mechanisms of ActionCD3 T-cell engagersB-lymphocyte antigen CD19 inhibitors
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsNeoplasm, ResidualLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[12] 
Global Approved IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma
Original Approved Country/TerritoryUnited States
Original Approved Date2014/12/03
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMicromet Inc
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Jiao Tong University School of MedicineAmgen Europe BvCharite University, Berlin, Germany +[14] 
Inactive CompaniesLudwig Maximilians University Of MunichBoehringer Ingelheim Pharma Gmbh & Co KgAmgen Research (Munich) Gmbh +[9] 
Active IndicationsNeoplasm, ResidualLymphoma, B-CellLymphoma, Non-Hodgkin +[11] 
Inactive IndicationsLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeL01XC19
Related LinksWikipediaDrugBankKEGG